Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 7/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580487 | 1.00 | PTGS2 (0.42) | PTGS2CD274PPARGPTGESALOX5 | |
| SCHEMBL5580460 | 0.89 | PPARD (0.42) | PPARGPTGESALOX5PSEN1NPC1 | |
| SCHEMBL5580463 | 0.89 | PPARD (0.42) | PPARGPTGESALOX5PSEN1NPC1 | |
| SCHEMBL5584038 | 0.88 | NR1H2 (0.41) | PPARGPTGESALOX5PSEN1NPC1 | |
| SCHEMBL5584040 | 0.88 | NR1H2 (0.41) | PPARGPTGESALOX5PSEN1NPC1 | |
| SCHEMBL3508623 | 0.86 | PPARG (0.43) | PPARGPTGESALOX5PSEN1NPC1 | |
| SCHEMBL3508626 | 0.86 | PPARG (0.43) | PPARGPTGESALOX5PSEN1NPC1 | |
| SCHEMBL5580737 | 0.84 | PPARD (0.41) | PPARGPTGESALOX5PSEN1NPC1 | |
| SCHEMBL5580733 | 0.84 | PPARD (0.41) | PPARGPTGESALOX5PSEN1NPC1 | |
| SCHEMBL5580704 | 0.84 | S1PR5 (0.39) | PPARGPTGESALOX5PSEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105959-A1 | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1604971-A1 | CINNAMYL ALCOHOL DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105959-A1 | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient | LPL, GPR119, EBP | PTGS2 1407/4885CD274 3969/4885PPARG 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.